https://scholars.lib.ntu.edu.tw/handle/123456789/568536
標題: | Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy | 作者: | TAI-CHUNG TSENG Yu M.-L. CHUN-JEN LIU Lin C.-L. Huang Y.-W. Hsu C.-S. CHEN-HUA LIU Kuo S.F.-T. Pan C.J.-H. Yang S.-S. Su C.-W. PEI-JER CHEN DING-SHINN CHEN JIA-HORNG KAO |
公開日期: | 2011 | 出版社: | International Medical Press Ltd | 卷: | 16 | 期: | 5 | 起(迄)頁: | 629-637 | 來源出版物: | Antiviral Therapy | 摘要: | Background: Pegylated interferon (PEG-IFN)-α-2a improves the hepatitis B e antigen (HBeAg) seroconversion rate in HBeAg-positive chronic hepatitis B patients. However, baseline factors predicting favourable responses to PEG-IFN-α-2a remain largely unknown. Methods: A total of 115 HBeAg-positive chronic hepatitis B patients who had a pre-therapy serum alanine aminotransferase (ALT) level over two times the upper limit of normal and received PEG-IFN-α-2a for 6-12 months were consecutively enrolled according to the local reimbursed guidelines. HBeAg seroconversion and combined response defined as HBeAg seroconversion, HBV-DNA level <20,000 IU/ml as well as ALT normalization at 6 months off therapy were primary and secondary therapeutic end points, respectively. Baseline viral factors, including viral load, genotype and major sequences of precore stop codon/ basal core promoter (BCP), and host factors, including three single nucleotide polymorphisms among the HLADPA1, HLA-DPB1 and IL28B regions, were determined to correlate with therapeutic end points. Results: HBeAg seroconversion and combined response rates were 26.1% and 18.3%, respectively. By multivariate analysis, BCP mutation (OR 8.04, 95% CI 2.00-32.28) and rs3077 G/G genotype (OR 3.49, 95% CI 1.12-10.84) were associated with a higher HBeAg seroconversion rate; BCP mutation (OR 9.28, 95% CI 1.92-44.99) and baseline viral load <2×106 IU/ml (OR 4.78, 95% CI 1.37-16.69) were associated with a higher combined response rate. Conclusions: BCP mutation is associated with higher HBeAg seroconversion and combined response rates at 6 months off therapy in HBeAg-positive chronic hepatitis B patients treated with PEG-IFN-α-2a. Genetic variants in the HLA-DPA1 region may also affect treatment-induced HBeAg seroconversion. ?2011 International Medical Press. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984539678&doi=10.3851%2fIMP1841&partnerID=40&md5=c9f912fa22642f1d1e3fdbd4ca8894ce https://scholars.lib.ntu.edu.tw/handle/123456789/568536 |
ISSN: | 1359-6535 | DOI: | 10.3851/IMP1841 | SDG/關鍵字: | alanine aminotransferase; hepatitis B(e) antigen; HLA DP antigen; HLA DPB1 antigen; peginterferon alpha2a; virus DNA; adult; alanine aminotransferase blood level; antiviral therapy; article; basal core promoter; controlled study; drug efficacy; female; gene mutation; gene sequence; genetic correlation; genetic variability; hepatitis B; Hepatitis B virus; human; major clinical study; male; nonhuman; outcome assessment; priority journal; prognosis; promoter region; seroconversion; single nucleotide polymorphism; stop codon; treatment duration; virus load; virus typing |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。